Compounded Medication – Prescription Only

This product is a compounded injectable formulation containing thymosin alpha-1 and is dispensed only pursuant to a valid prescription issued by a licensed healthcare provider. Thymosin alpha-1 is a synthetic peptide. In compounding practice, peptide formulations may be prescribed when a provider determines that individualized formulation, concentration, or dosing considerations are clinically appropriate for a specific patient. This product is not available for self-selection and may only be dispensed following provider authorization.

Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). The FDA does not evaluate compounded formulations for safety, effectiveness, or manufacturing quality. Compounding is performed by a state-licensed pharmacy pursuant to a patient-specific prescription. This page provides general, non-therapeutic information for educational and compliance purposes only. It does not describe intended use, therapeutic benefit, immune effects, physiologic outcomes, or expected clinical results.

General Scientific Information (Non-Therapeutic)

Thymosin alpha-1 has been referenced in scientific literature for its molecular structure and biochemical characteristics as a synthetic peptide. Descriptions of peptide composition or laboratory-observed signaling characteristics are provided solely for general scientific context. No claims are made regarding safety, effectiveness, immune function, disease modification, or suitability for any particular condition.

Formulation Considerations

Thymosin alpha-1 is supplied as a compounded sterile injectable formulation. Differences in concentration, vial size, or excipients reflect formulation and dispensing parameters determined by the compounding pharmacy and prescribing healthcare provider and do not imply differences in clinical effect or therapeutic outcome.

Contraindications

Thymosin alpha-1 should not be used in individuals who have a known hypersensitivity or allergy to thymosin alpha-1 or any component of the compounded formulation; have experienced prior adverse reactions to peptide-based injections; or have other conditions in which injectable peptide therapy is contraindicated as determined by the prescribing healthcare provider. Use in pregnant or breastfeeding individuals should occur only if a licensed healthcare provider determines that potential risks and benefits have been carefully evaluated.

Warnings and Precautions

Peptide-based injectable formulations may be associated with local or systemic reactions. Injectable administration should be performed only as prescribed and supervised by a licensed healthcare provider. Patients should inform their healthcare provider of all medical conditions, medications, and supplements prior to use. This product should not be used outside provider-directed protocols.

Potential Side Effects

Reported side effects associated with injectable peptide formulations may include injection-site reactions such as redness, swelling, irritation, or discomfort; headache; dizziness; flushing; nausea; or fatigue. Serious adverse reactions are uncommon but may occur. Patients should seek medical attention if they experience signs of a severe allergic reaction or unexpected systemic symptoms.